| 產(chǎn)品編號 | BIO1003SM |
| 英文名稱 | Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab Biosimilar) |
| 別 名 | CTLA-4 / CD152 & PDCD1 / PD-1 / CD279; Vudalimab |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 125.43kDa |
| 性 狀 | Lyophilized |
| 亞 型 | Half IgG+ScFv |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of Vudalimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Vudalimab was able to block the PD-1/PD-L1 signaling pathway.
Vudalimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Vudalimab bound to huPD-1-Jurkat cells, and the EC50 was 2.508 nM.
Vudalimab bound to CTLA4-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Vudalimab bound to CTLA4-CHO-K cells, and the EC50 was 20.150 nM.
Vudalimab bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vudalimab bound to huPD-1-His, and the EC50 was 0.090 nM.
Vudalimab bound to CTLA4 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vudalimab bound to hu-CTLA4-His, and the EC50 was 0.480 nM.
The purity of Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab) is 98.25%, determined by SEC-HPLC.
Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected molecular weight of Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab) is 125.32 kDa.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
